MAPK7 and breast carcinoma: Constitutively activated ERK5 was also reported to be associated with activated forms of ErbB2, ErbB3, and ErbB4 in human breast cancer cells and are related to shorter disease-free intervals, poor prognosis, resistance to chemotherapy, and increased risk of metastasis21–23.